Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)

Summary

This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT053 CAR-BCMA T in patients with relapsed and/or refractory multiple myeloma.

Conditions

• Multiple Myeloma

Interventions

BIOLOGICAL

CAR-BCMA T Cells

The CAR-BCMA T cells (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting BCMA.

Sponsors & Collaborators

• Beijing Chao Yang Hospital

  collaborator OTHER

• The First Affiliated Hospital of Soochow University

  collaborator OTHER

• Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

  collaborator OTHER

• Tianjin Medical University General Hospital

  collaborator OTHER

• First Affiliated Hospital of Zhejiang University

  collaborator OTHER

• Beijing Hospital

  collaborator OTHER_GOV

• Shanghai Tongji Hospital, Tongji University School of Medicine

  collaborator OTHER

• First Affiliated Hospital of Wenzhou Medical University

  collaborator OTHER

• Xiangya Hospital of Central South University

  collaborator OTHER

• Peking University People's Hospital

  collaborator OTHER

• Qilu Hospital of Shandong University

  collaborator OTHER

• Sun Yat-sen University

  collaborator OTHER

• First Affiliated Hospital, Sun Yat-Sen University

  collaborator OTHER

• CARsgen Therapeutics Co., Ltd.

  lead INDUSTRY

Principal Investigators

• Wenming CHEN, MD · Beijing Chao Yang Hospital

• Zhengzheng FU, MD · The First Affiliated Hospital of Soochow University

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-06-10

Primary Completion

2024-12-31

Completion

2025-12-31

Countries

• China

Study Locations